Program
Interleukin 1 Receptor Antagonist Protein
Also written as “Anakinra”, “Anakinra (Kineret®)” and “anakinra”.
Its studies are mostly in Arthritis, Rheumatoid · Arthritis, Juvenile · Familial Mediterranean Fever · COVID-19 · Still's Disease, Adult-Onset, led by 3 companies.
Drug pageInterleukin 1 Receptor Antagonist Protein: every studyAll 168 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 70 open or running | phase 4since May 20, 2005 | May 17, 2002 | none ahead |
| Swedish Orphan Biovitrumits history only | 61 open or running | phase 4since Oct 8, 2024 | Dec 13, 2016 | none ahead |
| Hamad Medicalits history only | 10 open or running | phase 3since Nov 24, 2020 | Nov 24, 2020 | none ahead |
Also a collaborator on its studies: Tigermed Consulting and CMIC Co, Ltd. Japan.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Amgen only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 17, 2002First studies: 3 phase 2 studiesFirst studyNCT00037648, NCT00037700, NCT00038298
- May 16, 2005Phase 2 study in OsteoarthritisNCT00110916 · 165 enrolled
- May 20, 2005Phase 4 study in Arthritis, RheumatoidNCT00111410
- Jun 30, 2005Phase 4 study in Arthritis, RheumatoidNCT00121043
- Jun 30, 2005Phase 3 study in Arthritis, RheumatoidNCT00117091
TargetBeta
“A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist ”NCIt, by rule
Other programs on IL1A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lutikizumab | AbbVie | phase 3 | 12 |
| ABBV-1451 | AbbVie | phase 1 | 1 |
Studies
All 7 Amgen leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00121043Arthritis, Rheumatoid | 4 | Completed | ||
| NCT00117091Arthritis, Rheumatoid | 3 | Completed | ||
| NCT00111410Arthritis, Rheumatoid | 4 | Completed | ||
| NCT00110916Osteoarthritis | 2 | Completed | Feb 2005 | 165 |
| NCT00038298Arthritis, Rheumatoid | 2 | Completed | May 2004 | 53 |
| NCT00037700Arthritis, Rheumatoid | 2 | Completed | ||
| NCT00037648Arthritis, Juvenile | 2 | Completed | Nov 2003 | 86 |
How it is read
Names in the registry
- “Anakinra”, 5 entries
- “Anakinra (Kineret®)”, 2 entries
- “anakinra”, 2 entries
- “AMG 719”, 2 entries
- “Anakinra 100 mg”, 1 entry
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 5 studies
- Arthritis, Juvenile, 3 studies
- Familial Mediterranean Fever, 1 study
- COVID-19, 1 study
- Still's Disease, Adult-Onset, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.